People and Business News — 5/22
People News
Rho has appointed Peter Schmidt, PhD, as Senior Vice President, Government Partnerships of Rho’s Federal Systems Division.
Syneos Health announced the promotions of Baba Shetty to President, Technology and Data Solutions, and Suma Ramadas to Executive Vice President, Medical Affairs.
Cytel Inc. has appointed Albert Kim, PhD, as its first Chief Medical Officer.
Greater Gift announces new board members, Clare Grace, Sharon Hanlon and Harsha Rajasimha.
HeartcoR Solutions announced that Dennis Bergau has joined the company as Vice President of Clinical Operations.
PHASTAR announced Ping-Chung Chang has joined the company as Head of China Development and Global Delivery.
Syneos Health announced the appointment of Michelle Keefe as CEO and a member of the Company’s Board of Directors.
Worldwide Clinical Trials announced Rosemarie Corrigan has joined the company as executive vice president, global quality.
physIQ announced the appointment of two new members to its executive leadership team. John Wilson has been named Senior Vice President and General Manager of Life Sciences, and Chris Englerth joins the team as Vice President of Marketing.
Business News
ActiGraph is the latest business to receive funding through the Industry Resilience and Diversification Fund.
Clinerion has received patent protection for their revolutionary ANID technology.
Emmes announced that it is providing data, statistical analysis, and project management support for new research that will test the Moderna mRNA vaccine at more than 50 sites in South and East Africa.
Clario announced the release of its first Environmental, Social and Governance Report.
Recognition
Northwestern University Feinberg School of Medicine Research Team:Robert F. Kushner, MD, Alicia Agnoli, MD, MPH, MHS, Lesley Inker, MD, and Chi-yuan Hsu, MD, MS
The Herbert Pardes Clinical Research Excellence Award, was given to a research team from Northwestern University Feinberg School of Medicine the study, Once-Weekly Semaglutide in Adults with Overweight or Obesity. Two additional Distinguished Clinical Research Achievement Awards (one shared) were presented for their creativity, innovation, and novel approach that demonstrated immediate impact on the health and well-being of patients to University of California, Davis and to Tufts University School of Medicine andUniversity of California San Francisco.
Rho was named the winner of a Silver Stevie Award in the Fastest Growing Company of the Year category in the 20th Annual American Business Awards.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
